Duc brings over twenty years of experience in drug discovery and drug development within big pharma and biotech.

Duc joined Step Pharma in March 2020. His drug development expertise extends across many therapeutic areas including cardiovascular, anti-infective, urology, epigenetics, CNS, rare disease and reproductive medicine, acquired through roles in big pharma (Sanofi-Aventis, Pfizer, Lundbeck) and biotech (Preglem, Arisgen, EspeRare, Prexton Therapeutics). He has successfully delivered a number of projects into clinical development and on to registration.

Duc graduated from the French Grandes Ecoles d’ingénieurs ESPCI in Physics, Chemistry and Biology. He also holds an MSc in organic and bio-organic chemistry from Paris VI and is a registered Project Manager.


Step Pharma is led by a highly motivated management team and an exceptional syndicate of international investors, all driven to bring about a step change in cancer treatment for patients.